Replies to post #197 on Sanofi - Contingent Value Rig (GCVRZ)

[ghmm]

My guess is a reaction to the NEJM article/letter on DMF and PML that there may be longer term use risk and seeing patient lymphocyte counts may not be enough to reduce risk. A lot of analysts defend BIIB and it was even up a little on the day.